

htd

hrvatsko
torakalno
društvo

Croatian
Thoracic
Society

MASTERCLASS

4.0.

MASTERCLASS IN THORACIC ONCOLOGY
ŠKOLA TORAKALNE ONKOLOGIJE

6 - 7. 2. 2026. | THE WESTIN ZAGREB HOTEL

Poštovane kolegice i kolege,

iznimna nam je čast pozvati Vas na Školu torakalne onkologije - Masterclass 4.0. koja će se održati 6. - 7. veljače 2026. u Zagrebu, u hotelu The Westin.


Ovogodišnji Masterclass donosi pregled najnovijih spoznaja i praktičnih smjernica iz područja dijagnostike i liječenja tumora pluća te drugih maligniteta torakalne regije. Program uključuje predavanja vodećih domaćih i međunarodnih stručnjaka, prikaze slučajeva te interaktivne rasprave osmišljene kako bi sudionicima pružile najnovije i klinički primjenjive informacije.

Cilj Škole je potaknuti razmjenu znanja i iskustava među specijalistima onkologije, pulmologije, radiologije, patologije, torakalne kirurgije te svim drugim stručnjacima uključenima u multidisciplinarno zbrinjavanje bolesnika s torakalnim malignitetima.

Masterclass 4.0. je izvrsna prilika za razmjenu znanja i iskustava među stručnjacima te za upoznavanje s najnovijim smjernicama i terapijskim pristupima u torakalnoj onkologiji.

Radujemo se Vašem dolasku i zajedničkom stručnom usavršavanju u Zagrebu!

Srdačno Vas pozdravljamo,



Prof. dr. sc. Marko Jakopović, dr. med
Predsjednik organizacijskog odbora
Hrvatsko torakalno društvo

Dear colleagues,

We are honoured to invite you to the Masterclass in Thoracic Oncology - Masterclass 4.0., which will be held February 6-7, 2026, at the Westin Zagreb Hotel.


This year's Masterclass will provide an overview of the latest knowledge and practical guidelines in the diagnosis and treatment of lung tumours and other malignancies of the thoracic region. The program includes lectures by leading national and international experts, case presentations, and interactive discussions designed to provide participants with the most up-to-date and clinically applicable information.

The goal of the Masterclass is to foster the exchange of knowledge and experience among specialists in oncology, pulmonology, radiology, pathology, thoracic surgery, and all other professionals involved in the multidisciplinary care of patients with thoracic malignancies.

Masterclass 4.0 is an excellent opportunity for exchanging knowledge and experience among experts and for becoming familiar with the latest guidelines and therapeutic approaches in thoracic oncology.

We look forward to welcoming you to Zagreb for this professional exchange!

With kind regards,



Prof. Marko Jakopović, PhD, MD
Chair of the Organizing Committee
Croatian Thoracic Society

htd | hrvatsko
torakalno
društvo | Croatian
Thoracic
Society

MASTERCLASS

4.0.

MASTERCLASS IN THORACIC ONCOLOGY
ŠKOLA TORAKALNE ONKOLOGIJE

6 - 7. 2. 2026. | THE WESTIN ZAGREB HOTEL

ORGANIZATOR | ORGANIZER:

Hrvatsko torakalno društvo

Croatian Thoracic Society

www.toraks.hr

htd

hrvatsko
torakalno
društvo

Croatian
Thoracic
Society

ORGANIZACIJSKI ODBOR |

ORGANIZING COMMITTEE:

Marko Jakopović, Fran Seiwerth,
Lela Bitar, Lidija Ljubičić, Sandra Karabatić

Pod pokroviteljstvom Akademije
medicinskih znanosti Hrvatske |
Under the auspices of the Croatian
Academy of Medical Sciences

PROGRAM LIJEČNICI | DOCTORS

htd | hrvatsko
onkološko
društvo | Croatian
Thoracic
Society

MASTERCLASS

4.0.

MASTERCLASS IN THORACIC ONCOLOGY
ŠKOLA TORAKALNE ONKOLOGIJE

6 - 7. 2. 2026. | THE WESTIN ZAGREB HOTEL

Friday, February 6th, 2026

11:30 - 12:00	Registration
	Diagnostics of lung cancer Chairpersons: Denis Baričević, Dražena Srdić
12:00 - 12:05	Opening remarks
12:05 - 12:20	Kristina Krpina Update on lung cancer screening
12:20 - 12:35	Ana Marija Alduk Peripheral nodules - outside in
12:35 - 12:50	Aleš Rozman Peripheral nodules - inside out
12:50 - 13:05	Silvana Smojver Ježek What can we get from cytology samples?
13:05 - 13:20	Monika Ulamec Importance of STAS in thoracic oncology
	Swixx <small>BioPharma</small>  Bristol Myers Squibb
13:20 - 13:35	Lidija Ljubičić Perioperative immunotherapy treatment in NSCLC patients without actionable mutations
13:35 - 13:50	Maximilian Hochmair Perioperative treatment in patients with NSCLC and actionable mutations
13:50 - 14:05	Marko Jakopović Can we tailor perioperative treatment?

14:05 - 14:25

Coffee break

14:25 - 14:55

Satellite symposium MSD

Maximilian Hochmair

Pembrolizumab: an established standard of care for NSCLC



Targeted treatments

Chairpersons: Davorin Radosavljević,
Sanja Pleština

14:55 - 15:10

Ivana Canjko

Can we tailor upfront treatment of ALK positive NSCLC?

15:10 - 15:25

Katja Mohorčić

**The right upfront treatment of EGFR positive NSCLC
- do we know the answer?**

15:25 - 15:40

Urška Janžić

Importance of co-mutations in NSCLC

15:40 - 15:55

Lela Bitar

HER2 NSCLC - can we do better?

15:55 - 16:10

Jasna Radić

KRAS positive lung cancer - what are the options?

16:10 - 16:25

Sanja Pleština

New targets in NSCLC

16:25 - 16:40

Tihana Pavić

Concomitant radiotherapy and targeted treatments or IO

htd | Hrvatsko
Onkološko
Društvo

Croatian
Thoracic
Society

MASTERCLASS

4.0.

MASTERCLASS IN THORACIC ONCOLOGY
ŠKOLA TORAKALNE ONKOLOGIJE

6 - 7. 2. 2026. | THE WESTIN ZAGREB HOTEL

16:40 - 17:00	Coffee break
	Translational medicine Chairpersons: Marko Jakopović, Urška Janžić
17:00 - 17:15	Rosa Karlič What is the role of microbiota in thoracic oncology
17:15 - 17:30	Marina Popović When we need testing for germ-line mutations?
17:30 - 17:45	Petar Ozretić Epitranscriptomics: RNA modifications and their regulators as a source of new cancer biomarkers and therapeutic targets
17:45 - 18:00	Tajana Silovski What can we learn from breast cancer treatment?
	Palliative care Chairpersons: Ana Bačelić Gabelica, Katja Mohorčič
18:00 - 18:15	Latinka Basara Psychological approach to end-of-life care
18:15 - 18:30	Ivo Planinc Cardio-oncology
18:30 - 18:45	Tomi Kovačević Can we define unfit patients for radical treatments (surgery, radiotherapy, chemotherapy...)?
18:45 - 19:00	Jasna Buć Hadžić The role of SBRT in metastatic lung cancer
20:30	Dinner

Saturday, February 7th, 2026

- 08:30 - 09:00 Registration
Chairpersons: Marko Jakopović, Tihana Pavić
- 09:00 - 09:15 Goran Madžarac
Robotic thoracic surgery
- 09:15 - 09:30 Thomas Klikovits
Selective vs complete nodal dissection in radical thoracic surgery
- 09:30 - 09:45 Bojan Zarić
Treatment of unresectable stage III NSCLC (PACIFIC and beyond)
- 09:45 - 10:15 **Satellite symposium ROCHE**
Lela Bitar, Fran Seiwert
Redefining ES-SCLC Treatment: Where We Are Today and Where We're Going
- 10:15 - 10:45 **Satellite symposium AstraZeneca**
Urška Janžič, Dražena Srdić
Treatment of Early-Stage NSCLC: AEGEAN and ADAURA — From Theory to Clinical Practice
- 10:45 - 11:15 **Coffee break**

htd

Hrvatsko
torakalno
društvo

Croatian
Thoracic
Society

MASTERCLASS

4.0.

MASTERCLASS IN THORACIC ONCOLOGY
ŠKOLA TORAKALNE ONKOLOGIJE

6 - 7. 2. 2026. | THE WESTIN ZAGREB HOTEL

Immunotherapy

Chairpersons: Bojan Zarić, Sanja Pleština

- | | |
|---------------|--|
| 11:15 - 11:30 | Dražena Srdić
Can we combine immunotherapy with targeted agents? |
| 11:30 - 11:45 | Jelena Spasić
Immunotherapy – how long is enough? |
| 11:45 - 12:00 | Fran Seiwerth
Immunotherapy – do we know the right dose? |
| 12:00 - 12:15 | Vide Popović
Is there a role for rechallenge of IO? |
| 12:15 - 12:30 | Suzana Mladinov
Who should not receive immunotherapy Today? |
| 12:30 - 12:45 | Marta Koršić
Efficacy of IO regarding smoking status |
| 12:45 - 13:00 | Dragan Trivanović
Can we improve patient care in thoracic oncology – experience from county hospital SCLC, thymomas and mesothelioma |
| 13:00 - 13:15 | Marijo Boban
What is new in SCLC? |
| 13:15 - 13:30 | Marko Jakopović
Novelties in mesothelioma and thymoma |
| 13:30 | Closing remarks |
| 13:45 | Lunch |

PROGRAM MEDICINSKE SESTRE U ONKOLOGIJI | ONCOLOGY NURSING PROGRAMME

htd | Hrvatsko
onkološko
društvo | Croatian
Thoracic
Society

MASTERCLASS

4.0.

MASTERCLASS IN THORACIC ONCOLOGY
ŠKOLA TORAKALNE ONKOLOGIJE

6 - 7. 2. 2026. | THE WESTIN ZAGREB HOTEL

Saturday, February 7th, 2026

- 09:00 – 09:20 Tihana Gašpert
Adherence in cancer patients and the importance of a non-pharmacological approach – bibliotherapy.
- 09:20 – 09:40 Petra Popović
Subcutaneous Administration of Therapy – Experience from Pula
- 09:40 – 10:10 **Satellite symposium AstraZeneca**
Ana Bačelić Gabelica, Sandra Karabatić
Recognizing and Managing Immunotherapy Adverse Events: Nursing Algorithms for Early Detection, Assessment, and Intervention
- 10:10 – 10:40 **Coffee break**
- 10:40 – 11:00 Maria Paula Požgaj, Marija Škrtić
Adverse Events of Immunotherapy and Nursing Documentation
- 11:00 – 11:20 Ivana Lukić Franolić
Lung Cancer: Multiple Faces of the Disease – Nursing Care Through Two Case Reports
- 11:20 – 11:40 Sandra Karabatić
Challenges Along the Patient’s Journey – A Case Report
- 11:40 – 12:00 Aleksandra Trupković
Interventional Bronchoscopy in Lung Cancer

12:00 - 12:30

Satellite symposium MSD

Dražena Srdić

Progress in treatment and care of patients with lung cancer

12:30 - 12:50

Anela Muratović

Experience with Targeted Therapy in Lung Cancer in Slovenia: Adverse Events and Nursing Care – A Case Report

13:00

Lunch


htd | Hrvatsko
onkološko
društvo | Croatian
Thoracic
Society


MASTERCLASS


4.0.


MASTERCLASS IN THORACIC ONCOLOGY
ŠKOLA TORAKALNE ONKOLOGIJE


6 - 7. 2. 2026. | THE WESTIN ZAGREB HOTEL



















Johnson & Johnson u onkologiji

Naša vizija: eliminirati rak

Naše nadahnuće i motivacija: bolesnici i njihove obitelji



Naše nasljeđe

Više od 30 godina iskustva u liječenju onkoloških bolesti učinilo nas je jednom od vodećih farmaceutskih kompanija u tom području.¹



Naša misija

Predani smo proaktivnoj borbi protiv raka i nastojimo bolesnicima ponuditi sinergijske terapijske protokole s ciljem izlječenja, a posebno smo usredotočeni na područja s najvećim neodgovorenim potrebama.



Naš razvojni program i napredak

Dosad je više od 1,7 milijuna bolesnika diljem svijeta primilo lijekove društva J&J odobrene za onkološke bolesti,² a od 2011. godine EMA je odobrila 12 novih lijekova.*

Reference:

¹ Kalantar-Zadeh, K. History of erythropoiesis-stimulating agents, the development of biosimilars and the future of anemia treatment in nephrology. *Am J Nephrol.* 2017;45(3):235-247 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405152/> ² J&J. Innovative medicine business overview. Dostupno na: https://s203.q4cdn.com/972069832/files/doc_downloads/2023/12/innovative-medicine-presentation.pdf

*Dacogen (decitabin), Zytiga (abirateron), Imbruvica (ibrutinib), Darzalex (daratumumab), Erleada (apalutamid), Darzalex (daratumumab) u supkutanoj formulaciji, Rybrevant (amivantamab), Carvykti (ciltafagen autoleuce), Tecvyli (teklistamab), Talvey (talkvetamab), Akeega (niraparib / abirateronacetat), Balversa (erdafitinib)

Johnson & Johnson

Johnson & Johnson SE d.o.o.
Oreškovićeva 6h, 10 010 Zagreb, Hrvatska

SAMO ZA ZDRAVSTVENE RADNIKE
CP-545518 | Datum pripreme: listopad 2025.

KEYTRUDA[®]

(pembrolizumab)



Samo za zdravstvene djelatnike.

Prije propisivanja, molimo pročitajte zadnji

odobreni Sažetak opisa svojstava lijeka i

Uputu o lijeku odobrene u RH.

Lijek se izdaje na ograničeni recept.

Merck Sharp & Dohme, d.o.o.

Ivana Lučića 2a, 10000 Zagreb, Hrvatska;

telefon: 01/ 66 11 333, faks: 01/ 66 11 350

HR-KEY-00732 Izrađeno u Hrvatskoj, 11/2025. Sva prava pridržana

Copyright ©2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

MERCK



METIME



TEPMETKO[®]

tepotinib

- ▼ Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo otkrivanje novih sigurnosnih informacija. Od zdravstvenih radnika se traži da prijave svaku sumnju na nuspojavu za ovaj lijek. Samo za zdravstvene radnike. Posljednji odobreni Sažetak opisa svojstava lijeka Tepmetko dostupan je na internetskoj stranici Europske agencije za lijekove <https://www.ema.europa.eu>. HR-TEP-00043; 10/2025



TAGRISSO[®]

osimertinib



AstraZeneca 

AstraZeneca d.o.o., Ulica Vjekoslava Heinzela 70, 10000 Zagreb,

Tel: +385 1 4628 000, www.astrazeneca.com

Veeva ID HR-8912, siječanj 2026.

SAMO ZA ZDRAVSTVENE RADNIKE

IMFINZI[®] durvalumab

50 mg/ml koncentrat za otopinu za infuziju



AstraZeneca 

AstraZeneca d.o.o., Ulica Vjekoslava Heinzela 70, 10000 Zagreb,

Tel: +385 1 4628 000, www.astrazeneca.com

Veeva ID HR-8911, siječanj 2026.

SAMO ZA ZDRAVSTVENE RADNIKE

POPIS SPONZORA

AstraZeneca 

 MSD

 Roche

MEDISON 

Swixx  BioPharma

 Bristol Myers Squibb™

Johnson & Johnson

BAUSCH+Health

Sqilline

PharmaS®

MERCK

Tehnički organizator



Penta d.o.o.
Izidora Kršnjavoga 25, 10000 Zagreb
Hrvatska
OIB: 3137549539

e-mail: silvija.matic@penta-zagreb.hr
Tel . +385 1 4628 613
Mob. +385 91 2015 004
www.penta-pco.com

htd | hrvatsko
torakalno
društvo | Croatian
Thoracic
Society

MASTERCLASS

4.0.

MASTERCLASS IN THORACIC ONCOLOGY
ŠKOLA TORAKALNE ONKOLOGIJE

6 - 7. 2. 2026. | THE WESTIN ZAGREB HOTEL



htd | hrvatsko
torakalno
društvo